Neuroendocrine Small Cell Carcinoma of the Uterine Cervix: What Disease? What Treatment? Report of Ten Cases and a Review of the Literature

Delaloge, Suzette; Pautier, Patricia; Kerbrat, Pierre; Castaigne, D.; Haie-Méder, Christine; Duvillard, P.; Guivarch, C; Goupil, A; Borel, C.; Lhommé, C.

doi:10.1053/clon.2000.9194

Cited by 49 publications

(37 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 82 early-stage SCCUC patients who had undergone SU with or without adjuvant therapy were identified by a search on PubMed (3,4,9,(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30). The total number of patients for analysis was 96.…”

Section: Resultsmentioning

confidence: 99%

Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix

2011

View full text Add to dashboard Cite

Abstract. Small cell carcinoma of the uterine cervix (SCCUC) is rare and its biologic behavior is aggressive. To analyze prognostic factors and determine optimal therapy in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA SCCUC, we retrospectively reviewed 96 patients (14 patients treated in our center and 82 patients identified by a search on PubMed) treated with radical surgery (SU), surgery plus adjuvant chemotherapy (SU+Chemo), or surgery plus adjuvant chemotherapy and radiotherapy (SU+Chemo+RT) between 1990 and 2010. Of the 96 patients, 11 patients were treated with SU, 33 with SU+Chemo, and 52 with SU+Chemo+RT. The 5-year survival rate for the 96 patients was 45%. A total of 6% (2/32) of patients had local recurrence, 75% (24/32) had distant metastases, and 19% (6/32) had both. The 5-year survival rate in stage IB1 and IB2-IIA disease was 58 and 34%, respectively (P=0.049). For patients with and without lymph node metastases (LNM), survival was 33 and 60%, respectively (P=0.045). Patients with inner 1/3 stromal invasion had a better survival than those with deep stromal invasion (DSI) (100 vs. 34%, P=0.003). Survival was not significantly different in patients treated with the above three modalities, albeit treatment selection was related to LNM (P=0.000) and DSI (P=0.027). Thus, FIGO stage, LNM and DSI are significant predictors of survival. Adjuvant therapy after SU has not improved survival compared with surgery alone. Thus, newer multimodality therapy should be evaluated.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix

2011

View full text Add to dashboard Cite

show abstract

“…We therefore carried out a retrospective multicenter trial to identify the clinical and pathologic factors prognostic of survival, and to determine optimal treatment strategies for patients with early stage SCNEC. Table 3 is a review of literature published until a recent date for SCNEC [3,5,[10][11][12][13][14][15][16][17]. Large tumor size, lymph node metastases, smoking, stage, deep stromal invasion and a pure histologic type have been indicated as possible poor prognostic factors [3-5, 10, 12, 13, 18].…”

Section: Annals Of Oncologymentioning

confidence: 99%

Prognostic factors in FIGO stage IB–IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study

et al. 2008

View full text Add to dashboard Cite

Results: Of the 68 patients, 43 had FIGO stage IB1 SCNEC, 15 had stage IB2, and 10 had stage IIA. Seven were treated with radical surgery alone; 11 with neoadjuvant chemotherapy (NACT) followed by radical surgery; 24 with radical surgery followed by adjuvant chemotherapy; and 26 with radical surgery followed by adjuvant radiation or chemoradiation. After a median follow-up of 44 months (range, 6-113 months), the 2-year and 5-year survival rates for all patients were 64.6% and 46.6%, respectively. Univariate and multivariate analysis showed that FIGO stage was predictive of poor prognosis. Patients who received NACT showed poorer prognosis than those who did not receive NACT. Adjuvant chemoradiation did not improve survival compared with adjuvant chemotherapy alone.Conclusions: FIGO stage may act as a surrogate for factors prognostic of survival. Primary radical surgery followed by adjuvant chemotherapy is the preferred treatment modality for patients with early stage SCNEC.

show abstract

Section: Introductionmentioning

confidence: 99%

“…It mixes clinical and biological characteristics of both cervical neoplasms and neuroendocrine SCC of any site, making it an original nosologic entity [3]. SCC accounts for 1-3% of all cervical neoplasms [3,4]. The diagnosis of neuroendocrine SCC requires the presence of small round or fusiform cells with scanty cytoplasm, frequent mitoses, hyperchromatic nuclei having finely granular chromatin, and absent or inconspicuous nucleoli, with or without positive staining of neuroendocrine markers [3,5].…”

Section: Introductionmentioning

confidence: 99%

“…The diagnosis of neuroendocrine SCC requires the presence of small round or fusiform cells with scanty cytoplasm, frequent mitoses, hyperchromatic nuclei having finely granular chromatin, and absent or inconspicuous nucleoli, with or without positive staining of neuroendocrine markers [3,5]. Indeed, the main characteristic of this tumour is its poor prognosis [3]. The optimal treatment has not yet been completely clarifi ed [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation